On February 23, 2026, BioMarin Pharmaceutical Inc. has announced that it has decided to pull the hemophilia A gene therapy ROCTAVIAN (valoctocogene roxaparvovec-rvox) from the market. The decision follows the company’s announcement in October 2025 that it would explore options to divest ROCTAVIAN and seek a potential buyer with an established presence in hematology or gene therapy.

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic

Ti diamo il benvenuto in WordPress. Questo è il tuo primo articolo. Modificalo o eliminalo e quindi inizia a scrivere!